SCHEMBL4069200

SCHEMBL4069200

COC(=O)[C@H](Cc1ccc(CCCc2cccc(N(C)C(=O)OC(C)(C)C)n2)cn1)NC(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 3/20 0.43
ITGA5 P08648 3/20 0.43
KLK5 Q9Y337 1/20 0.38
HDAC6 Q9UBN7 4/20 0.35
HDAC1 Q13547 2/20 0.35
PSEN1 P49768 2/20 0.35
PSEN2 P49810 2/20 0.35
APH1B Q8WW43 2/20 0.35
NCSTN Q92542 2/20 0.35
APH1A Q96BI3 2/20 0.35
PSENEN Q9NZ42 2/20 0.35
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
PTPN1 P18031 2/20 0.34
CTSS P25774 4/20 0.34
CTSK P43235 4/20 0.34
CKS1B P61024 1/20 0.34
SKP1 P63208 1/20 0.34
SKP2 Q13309 1/20 0.34
CTSB P07858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8227097 1.00 ITGB1 (0.43) ITGB1ITGA5KLK5HDAC6HDAC1
SCHEMBL4074572 0.91 KLK5 (0.44) ITGB1ITGA5KLK5PSEN1PSEN2
SCHEMBL8228529 0.89 KLK5 (0.44) ITGB1ITGA5KLK5PSEN1PSEN2
SCHEMBL4067205 0.89 KLK5 (0.44) ITGB1ITGA5KLK5PSEN1PSEN2
SCHEMBL4071990 0.87 ITGB1 (0.44) ITGB1ITGA5KLK5HDAC6ITGB3
SCHEMBL4064751 0.83 ITGAV (0.42) ITGB1ITGA5KLK5HDAC6HDAC1
SCHEMBL4068719 0.83 KLK5 (0.35) KLK5HDAC6HDAC1PTPN1CTSS
SCHEMBL4068714 0.83 KLK5 (0.35) KLK5HDAC6HDAC1PTPN1CTSS
SCHEMBL4205174 0.81 SUCNR1 (0.42) ITGB1ITGA5KLK5HDAC6HDAC1
SCHEMBL4067093 0.81 KLK5 (0.42) ITGB1ITGA5KLK5HDAC6HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049490-A1 N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL]-L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS Astra Zeneca AB (SE) 2009-04-22 EP disclosed
US-20080045521-A1 PHENYLALANINE DERIVATIVES ASTRAZENECA AB (SE) 2008-02-21 US disclosed
US-20080045521-A1 PHENYLALANINE DERIVATIVES ASTRAZENECA AB (SE) 2008-02-21 US disclosed
US-20080045521-A1 PHENYLALANINE DERIVATIVES ASTRAZENECA AB (SE) 2008-02-21 US disclosed
WO-2007141473-A1 N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS ASTRAZENECA AB (SE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045521-A1 PHENYLALANINE DERIVATIVES ITGB5, ITGB1, ITGA2B ITGB1 2/4885ITGA5 7/4885KLK5 2412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.